ArticleOncotarget2018
Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Regret concerning treatment decisions in patients with primary or secondary brain tumors - a cross-sectional exploratory bicentric analysis.Journal of neuro-oncology · 2026Article
- Clinical outcomes of adding vincristine to procarbazine-lomustine in patients with gliomas: insights from current evidence.Ecancermedicalscience · 2026Article
- A novel HPβCD-Cu(DDC)Scientific reports · 2025Article
- Nanoparticle-Based Approaches in the Diagnosis and Treatment of Brain Tumors.Journal of clinical medicine · 2024Review
- Review
- Review
- miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review.Journal of the Egyptian National Cancer Institute · 2024Review
- High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.Frontiers in oncology · 2024Review
- Review
- How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology?Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2022Review
- Synchronous supratentorial and infratentorial oligodendrogliomas with incongruous IDH1 mutations, a case report.Acta neuropathologica communications · 2021Article
- Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.Molecules (Basel, Switzerland) · 2021Review
- Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.Cancer research · 2020Article
- PIWI-interacting RNAs and PIWI proteins in glioma: molecular pathogenesis and role as biomarkers.Cell communication and signaling : CCS · 2020Review
- Rehabilitation of Adult Patients with Primary Brain Tumors: A Narrative Review.Brain sciences · 2020Review
- Article
- Effects of temozolomide on U87MG glioblastoma cell expression of CXCR4, MMP2, MMP9, VEGF, anti-proliferatory cytotoxic and apoptotic properties.Molecular biology reports · 2020Article
- MicroRNA-16 Inhibits Glioblastoma Growth in Orthotopic Model by Targeting Cyclin D1 and WIP1.OncoTargets and therapy · 2020Article
- Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit.Frontiers in oncology · 2020Article
- Discovery of potential targets of Triptolide through inverse docking in ovarian cancer cells.PeerJ · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-grade gliomas (LGG) encompass a heterogeneous group of tumors that are clinically, histologically and molecularly diverse. Treatment decisions for patients with LGG are directed toward improving upon the natural history while limiting treatment-associated toxiceffects. Recent evidence has documented a utility for adjuvant chemotherapy with procarbazine, CCNU (lomustine), and vincristine (PCV) or temozolomide (TMZ). We sought to determine the comparative utility of PCV and TMZ for patients with LGG, particularly in context of molecular subtype. A literature search of PubMed was conducted to identify studies reporting patient response to PCV, TMZ, or a combination of chemotherapy and radiation therapy (RT). Eligibility criteria included patients 16 years of age and older, notation of LGG subtype, and report of progression-free survival (PFS), overall survival (OS), and treatment course. Level I, II, and III data were included. Adjuvant therapy with PCV resulted in prolonged PFS and OS in patients with newly diagnosed high-risk LGG. This benefit was accrued most significantly by patients with tumors harboring 1p/19q codeletion and IDH1 mutation. Adjuvant therapy with temozolomide was associated with lower toxicity than therapy with PCV. In patients with LGG with an unfavorable natural history, such as with intact 1p/19q and wild-type IDH1, RT/TMZ plus adjuvant TMZ may be the best option. Patients with biologically favorable high-risk LGG are likely to derive the most benefit from RT and adjuvant PCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.